Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Jun 1;99(11):2625–2634. doi: 10.1172/JCI119451

Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.

M Ziche 1, L Morbidelli 1, R Choudhuri 1, H T Zhang 1, S Donnini 1, H J Granger 1, R Bicknell 1
PMCID: PMC508108  PMID: 9169492

Abstract

Systemic administration of the nitric oxide (NO) synthase inhibitor Nomega-nitro--arginine methyl ester (L-NAME) to rabbits bearing a corneal implant blocked vascular endothelial growth factor (VEGF), but not basic fibroblast growth factor (bFGF)-induced angiogenesis. L-NAME completely blocked angiogenesis induced by VEGF-transfected MCF-7 breast carcinoma cells and the cells remained dormant in the cornea. Postcapillary endothelial cell migration and growth induced by VEGF were blocked by both the NO synthase inhibitor Nomega-mono-methyl--arginine and by the guanylate cyclase inhibitor LY 83583. We conclude that NO is a downstream imperative of VEGF-, but not bFGF-induced angiogenesis, and propose that the NO synthase/guanylate cyclase pathway is a potential target for controlling tumor angiogenesis in response to VEGF. Our studies support recent evidence that VEGF and bFGF induce angiogenesis by different mechanistic pathways using the alphavbeta5 and alphavbeta3 integrins, respectively.

Full Text

The Full Text of this article is available as a PDF (590.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asano M., Yukita A., Matsumoto T., Kondo S., Suzuki H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Res. 1995 Nov 15;55(22):5296–5301. [PubMed] [Google Scholar]
  2. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1006/abio.1976.9999. [DOI] [PubMed] [Google Scholar]
  3. Brock T. A., Dvorak H. F., Senger D. R. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol. 1991 Jan;138(1):213–221. [PMC free article] [PubMed] [Google Scholar]
  4. Brown L. F., Berse B., Jackman R. W., Tognazzi K., Manseau E. J., Dvorak H. F., Senger D. R. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol. 1993 Nov;143(5):1255–1262. [PMC free article] [PubMed] [Google Scholar]
  5. Brzozowski T., Konturek S. J., Drozdowicz D., Dembiński A., Stachura J. Healing of chronic gastric ulcerations by L-arginine. Role of nitric oxide, prostaglandins, gastrin and polyamines. Digestion. 1995;56(6):463–471. doi: 10.1159/000201277. [DOI] [PubMed] [Google Scholar]
  6. Claffey K. P., Brown L. F., del Aguila L. F., Tognazzi K., Yeo K. T., Manseau E. J., Dvorak H. F. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996 Jan 1;56(1):172–181. [PubMed] [Google Scholar]
  7. Cobbs C. S., Brenman J. E., Aldape K. D., Bredt D. S., Israel M. A. Expression of nitric oxide synthase in human central nervous system tumors. Cancer Res. 1995 Feb 15;55(4):727–730. [PubMed] [Google Scholar]
  8. Doi K., Akaike T., Horie H., Noguchi Y., Fujii S., Beppu T., Ogawa M., Maeda H. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer. 1996 Apr 15;77(8 Suppl):1598–1604. doi: 10.1002/(SICI)1097-0142(19960415)77:8<1598::AID-CNCR27>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  9. Ferrara N., Henzel W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989 Jun 15;161(2):851–858. doi: 10.1016/0006-291x(89)92678-8. [DOI] [PubMed] [Google Scholar]
  10. Friedlander M., Brooks P. C., Shaffer R. W., Kincaid C. M., Varner J. A., Cheresh D. A. Definition of two angiogenic pathways by distinct alpha v integrins. Science. 1995 Dec 1;270(5241):1500–1502. doi: 10.1126/science.270.5241.1500. [DOI] [PubMed] [Google Scholar]
  11. Gasparini G., Weidner N., Bevilacqua P., Maluta S., Dalla Palma P., Caffo O., Barbareschi M., Boracchi P., Marubini E., Pozza F. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol. 1994 Mar;12(3):454–466. doi: 10.1200/JCO.1994.12.3.454. [DOI] [PubMed] [Google Scholar]
  12. Harris D. N., Asaad M. M., Phillips M. B., Goldenberg H. J., Antonaccio M. J. Inhibition of adenylate cyclase in human blood platelets by 9-substituted adenine derivatives. J Cyclic Nucleotide Res. 1979;5(2):125–134. [PubMed] [Google Scholar]
  13. Houck K. A., Ferrara N., Winer J., Cachianes G., Li B., Leung D. W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol. 1991 Dec;5(12):1806–1814. doi: 10.1210/mend-5-12-1806. [DOI] [PubMed] [Google Scholar]
  14. Jenkins D. C., Charles I. G., Thomsen L. L., Moss D. W., Holmes L. S., Baylis S. A., Rhodes P., Westmore K., Emson P. C., Moncada S. Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4392–4396. doi: 10.1073/pnas.92.10.4392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kandel J., Bossy-Wetzel E., Radvanyi F., Klagsbrun M., Folkman J., Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 1991 Sep 20;66(6):1095–1104. doi: 10.1016/0092-8674(91)90033-u. [DOI] [PubMed] [Google Scholar]
  16. Keck P. J., Hauser S. D., Krivi G., Sanzo K., Warren T., Feder J., Connolly D. T. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989 Dec 8;246(4935):1309–1312. doi: 10.1126/science.2479987. [DOI] [PubMed] [Google Scholar]
  17. Kim K. J., Li B., Winer J., Armanini M., Gillett N., Phillips H. S., Ferrara N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993 Apr 29;362(6423):841–844. doi: 10.1038/362841a0. [DOI] [PubMed] [Google Scholar]
  18. Klagsbrun M., Sasse J., Sullivan R., Smith J. A. Human tumor cells synthesize an endothelial cell growth factor that is structurally related to basic fibroblast growth factor. Proc Natl Acad Sci U S A. 1986 Apr;83(8):2448–2452. doi: 10.1073/pnas.83.8.2448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ku D. D., Zaleski J. K., Liu S., Brock T. A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am J Physiol. 1993 Aug;265(2 Pt 2):H586–H592. doi: 10.1152/ajpheart.1993.265.2.H586. [DOI] [PubMed] [Google Scholar]
  20. Leibovich S. J., Polverini P. J., Fong T. W., Harlow L. A., Koch A. E. Production of angiogenic activity by human monocytes requires an L-arginine/nitric oxide-synthase-dependent effector mechanism. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4190–4194. doi: 10.1073/pnas.91.10.4190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Millauer B., Shawver L. K., Plate K. H., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 1994 Feb 10;367(6463):576–579. doi: 10.1038/367576a0. [DOI] [PubMed] [Google Scholar]
  22. Moncada S., Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993 Dec 30;329(27):2002–2012. doi: 10.1056/NEJM199312303292706. [DOI] [PubMed] [Google Scholar]
  23. Morbidelli L., Chang C. H., Douglas J. G., Granger H. J., Ledda F., Ziche M. Nitric oxide mediates mitogenic effect of VEGF on coronary venular endothelium. Am J Physiol. 1996 Jan;270(1 Pt 2):H411–H415. doi: 10.1152/ajpheart.1996.270.1.H411. [DOI] [PubMed] [Google Scholar]
  24. Myoken Y., Kayada Y., Okamoto T., Kan M., Sato G. H., Sato J. D. Vascular endothelial cell growth factor (VEGF) produced by A-431 human epidermoid carcinoma cells and identification of VEGF membrane binding sites. Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5819–5823. doi: 10.1073/pnas.88.13.5819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mülsch A., Busse R., Liebau S., Förstermann U. LY 83583 interferes with the release of endothelium-derived relaxing factor and inhibits soluble guanylate cyclase. J Pharmacol Exp Ther. 1988 Oct;247(1):283–288. [PubMed] [Google Scholar]
  26. O'Brien T., Cranston D., Fuggle S., Bicknell R., Harris A. L. Different angiogenic pathways characterize superficial and invasive bladder cancer. Cancer Res. 1995 Feb 1;55(3):510–513. [PubMed] [Google Scholar]
  27. Orucevic A., Lala P. K. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice. Br J Cancer. 1996 Jan;73(2):189–196. doi: 10.1038/bjc.1996.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Parenti A., Amerini S., Ledda F., Maggi C. A., Ziche M. The tachykinin NK1 receptor mediates the migration-promoting effect of substance P on human skin fibroblasts in culture. Naunyn Schmiedebergs Arch Pharmacol. 1996 Apr;353(5):475–481. doi: 10.1007/BF00169165. [DOI] [PubMed] [Google Scholar]
  29. Pipili-Synetos E., Papageorgiou A., Sakkoula E., Sotiropoulou G., Fotsis T., Karakiulakis G., Maragoudakis M. E. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol. 1995 Sep;116(2):1829–1834. doi: 10.1111/j.1476-5381.1995.tb16670.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Pipili-Synetos E., Sakkoula E., Haralabopoulos G., Andriopoulou P., Peristeris P., Maragoudakis M. E. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol. 1994 Mar;111(3):894–902. doi: 10.1111/j.1476-5381.1994.tb14822.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Plate K. H., Breier G., Weich H. A., Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992 Oct 29;359(6398):845–848. doi: 10.1038/359845a0. [DOI] [PubMed] [Google Scholar]
  32. Schelling M. E., Meininger C. J., Hawker J. R., Jr, Granger H. J. Venular endothelial cells from bovine heart. Am J Physiol. 1988 Jun;254(6 Pt 2):H1211–H1217. doi: 10.1152/ajpheart.1988.254.6.H1211. [DOI] [PubMed] [Google Scholar]
  33. Shweiki D., Itin A., Soffer D., Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 1992 Oct 29;359(6398):843–845. doi: 10.1038/359843a0. [DOI] [PubMed] [Google Scholar]
  34. Taraboletti G., Roberts D., Liotta L. A., Giavazzi R. Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol. 1990 Aug;111(2):765–772. doi: 10.1083/jcb.111.2.765. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Thomsen L. L., Lawton F. G., Knowles R. G., Beesley J. E., Riveros-Moreno V., Moncada S. Nitric oxide synthase activity in human gynecological cancer. Cancer Res. 1994 Mar 1;54(5):1352–1354. [PubMed] [Google Scholar]
  36. Toi M., Kondo S., Suzuki H., Yamamoto Y., Inada K., Imazawa T., Taniguchi T., Tominaga T. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer. 1996 Mar 15;77(6):1101–1106. doi: 10.1002/(sici)1097-0142(19960315)77:6<1101::aid-cncr15>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  37. Wolff J. E., Guerin C., Laterra J., Bressler J., Indurti R. R., Brem H., Goldstein G. W. Dexamethasone reduces vascular density and plasminogen activator activity in 9L rat brain tumors. Brain Res. 1993 Feb 26;604(1-2):79–85. doi: 10.1016/0006-8993(93)90354-p. [DOI] [PubMed] [Google Scholar]
  38. Wu H. M., Huang Q., Yuan Y., Granger H. J. VEGF induces NO-dependent hyperpermeability in coronary venules. Am J Physiol. 1996 Dec;271(6 Pt 2):H2735–H2739. doi: 10.1152/ajpheart.1996.271.6.H2735. [DOI] [PubMed] [Google Scholar]
  39. Zhang H. T., Craft P., Scott P. A., Ziche M., Weich H. A., Harris A. L., Bicknell R. Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst. 1995 Feb 1;87(3):213–219. doi: 10.1093/jnci/87.3.213. [DOI] [PubMed] [Google Scholar]
  40. Ziche M., Gullino P. M. Angiogenesis and neoplastic progression in vitro. J Natl Cancer Inst. 1982 Aug;69(2):483–487. [PubMed] [Google Scholar]
  41. Ziche M., Jones J., Gullino P. M. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst. 1982 Aug;69(2):475–482. [PubMed] [Google Scholar]
  42. Ziche M., Morbidelli L., Masini E., Amerini S., Granger H. J., Maggi C. A., Geppetti P., Ledda F. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 1994 Nov;94(5):2036–2044. doi: 10.1172/JCI117557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Ziche M., Morbidelli L., Masini E., Granger H., Geppetti P., Ledda F. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun. 1993 May 14;192(3):1198–1203. doi: 10.1006/bbrc.1993.1543. [DOI] [PubMed] [Google Scholar]
  44. Ziche M., Morbidelli L., Pacini M., Geppetti P., Alessandri G., Maggi C. A. Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells. Microvasc Res. 1990 Sep;40(2):264–278. doi: 10.1016/0026-2862(90)90024-l. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES